Gilead Unit Reports Encouraging Phase 1 Data Showing High Response Rates for Bicistronic CAR T-Cell Candidates in B-Cell Lymphoma

MT Newswires Live12-08

Gilead Sciences' (GILD) Kite unit said Friday that two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, showed encouraging efficacy and safety results in a phase 1 study in patients with relapsed or refractory large B-cell lymphoma.

Both therapies target CD19 and CD20 antigens and use CD28 and 4-1BB co-stimulatory domains, the company said.

The open-label study enrolled 67 patients, including 30 treated with KITE-753 and 37 with KITE-363, Kite said.

At dose level three of KITE-753, 11 of 14 CAR-naive patients achieved a complete response at a median 2.9-month follow-up, the company said.

For KITE-363, the company reported durable benefit at the highest dose, with over 70% of complete responders remaining in remission at 12 months after a median 17.5-month follow-up.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment